EyePoint, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
EyePoint, Inc.
0.34
−85.28%
vs ±69.4% implied · ×1.23
shaded = implied · ▲▼ = realized
EyePoint has 3 disclosed suppliers and 4 disclosed customers in SEC filings.
SentenceUnder an Asset Purchase Agreement with Aerpio Pharmaceuticals Inc. (Aerpio) in 2021, we acquired all right title and interest in and to certain U.S. and ex-U.S. patents and applications relating to certain TIE-2 activating molecules, including razuprotafib.
EYPT 10-Kaccession 0001193125-26-093917
SentenceThe development and commercialization of our lead product candidate, DURAVYU, is dependent on intellectual property we license from Equinox Science and active pharmaceutical ingredient (API) supply of vorolanib.
EYPT 10-Kaccession 0001193125-26-093917
SentenceWe source the API from Farmabios, needles from a third party supplier and various other raw materials and components for YUTIQ ® from additional third-party vendors.
EYPT 10-Kaccession 0001193125-26-093917
SentenceWe originally licensed our Durasert ® proprietary insert technology to ANI for use in ILUVIEN for the treatment of all ocular diseases (excluding uveitis).
EYPT 10-Kaccession 0001193125-26-093917
SentenceUnder the Betta License Agreement, the Company granted to Betta an exclusive, sublicensable, royalty-bearing license under certain of the Company's intellectual property to develop, use (but not make or have made), sell, offer for sale, and import the Company's product candidate, DURAVYU, an investigational sustained delivery intravitreal anti-VEGF treatment that combines a bioerodible formulation of the Company's proprietary sustained-release technology with the compound vorolanib (the Licensed Product), in the field of ophthalmology (the Betta Field) in the Greater Area of China, including China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan (the Betta Territory).
EYPT 10-Kaccession 0001193125-26-093917
SentenceWe have licensed clinical development, regulatory, reimbursement and distribution rights to YUTIQ ® to Ocumension for Mainland China, Hong Kong, Macau, Taiwan, South Korea, and other jurisdictions across Southeast Asia.
EYPT 10-Kaccession 0001193125-26-093917
Linked news
Expected move
No implied move.